Oncology Drugs News

Written By Medical Oncology Group

6 May 2025 

MOGA is considering advocating for a change in PBS-wording or apply for unrestricted indication to allow zoledronic acid and denosumab to be used prophylactically in anyone on ADT to prevent SRE. 

Medical Oncology Group
Previous

MOGA Young Oncologists to attend ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025
Next

Driving Change: GEM and MDI Action Plans Making Strong Progress Across the RACP